Downregulation of DDIT4 ameliorates abnormal behaviors in autism by inhibiting ferroptosis via the PI3K/Akt pathway.

Scientists studied a protein called DDIT4 in mouse models of autism. They found that when this protein is high, it causes brain cell damage that may contribute to autism behaviors. When they reduced DDIT4 levels, the mice showed improvements in social behavior, repetitive actions, and anxiety. This early research suggests a new way that brain cells might be damaged in autism, but much more research is needed before this could lead to treatments for people.

This preclinical study investigated the role of DDIT4 protein and ferroptosis (a type of cell death) in autism spectrum disorder using both cell culture and mouse models. Researchers found that autistic mice showed elevated levels of oxidative stress markers and increased DDIT4 expression. When DDIT4 was reduced, it activated the PI3K/Akt cellular pathway, which decreased ferroptosis and improved autism-like behaviors including social deficits, repetitive behaviors, and anxiety. The study suggests that DDIT4 promotes neuronal cell death through ferroptosis by inhibiting protective cellular pathways, and that targeting this mechanism could potentially improve autism symptoms.

However, this research is entirely preclinical and requires significant validation before any clinical applications.

This preclinical research identifies novel molecular pathways potentially involved in autism pathology. While promising for future drug development targeting DDIT4 or ferroptosis, extensive clinical validation is required. Current findings cannot guide clinical practice but may inform future research directions for autism therapeutics.

Study is entirely preclinical using cell cultures and mouse models. Sample sizes not reported. Single study without replication. Unclear generalizability to human autism. No assessment of long-term effects or safety profiles of interventions tested.

Autism spectrum disorder (ASD) is a complex disease with unclear etiology. Studies have shown that ferroptosis is also related to ASD progression, but the specific mechanism is still unclear. Valproic acid (VPA) induced neuronal ferroptosis in vitro. Mechanistic studies showed that both VPA and ferroptosis inducers promoted the expression of DDIT4 in neurons, thereby inhibiting the activation of the PI3K/Akt pathway.

DDIT4 increased the accumulation of ROS, MDA and Fe, inhibited neuronal viability and downregulated GPX4 expression by inactivating the PI3K/Akt pathway. Ferroptosis inhibitors reversed the anti-survival effect of DDIT4, indicating that DDIT4 enhances ferroptosis through the PI3K/Akt pathway, thereby inhibiting neuronal viability. Further in vivo experiments found that autistic mice had high levels of ROS, MDA and Fe, increased DDIT4 expression, and downregulated expression levels of GPX4, p-PI3K and p-Akt; after downregulation of DDIT4 expression, the accumulation of ROS, MDA and Fewas significantly reduced, while the expression levels of GPX4, p-PI3K and p-Akt were upregulated, indicating that DDIT4 knockdown reduces ferroptosis in autistic mice. In addition, DDIT4 downregulation, PI3K/Akt pathway activation, and ferroptosis inhibitors all improved social behavior deficits, repetitive stereotyped and compulsive behaviors, anxiety and exploratory behaviors in autistic mice, but PI3K/Akt pathway inhibitors significantly blocked the rescue of abnormal behaviors by DDIT4 downregulation in autistic mice.

Therefore, downregulation of DDIT4 expression ameliorates abnormal behaviors in autism by inhibiting ferroptosis via the PI3K/Akt pathway, indicating that DDIT4, the PI3K/Akt pathway and ferroptosis have key roles in autism.